Viromed Medical AG

Viromed Medical AG plans to acquire all shares of ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights

13 September 2024

12:31 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Perbamed Invest GmbH, buy

12:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

12:28 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

3 September 2024

10:02 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

10:02 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

2 September 2024

10:00 Corporate

Viromed Medical AG

Corporate

Viromed Medical AG: Successful start of trading on XETRA

10 July 2024

07:30 Corporate

Viromed Medical AG

Corporate

Viromed Medical AG seeks special approval for cold plasma device for the prevention of ventilator-associated pneumonia (VAP)

5 July 2024

17:30 Ad-hoc

Viromed Medical AG

Ad-hoc

Viromed Medical AG: Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect

1 July 2024

18:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

18:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

18:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

18:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

26 April 2024

11:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Uwe Perbandt, buy

11:30 Directors’ Dealings

Viromed Medical AG

Directors’ Dealings

Viromed Medical AG: Perbamed Invest GmbH, buy

22 April 2024

16:30 Corporate

Viromed Medical AG

Corporate

Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential

13:05 Ad-hoc

Viromed Medical AG

Ad-hoc

Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected

17 April 2024

12:05 Ad-hoc DE

Viromed Medical AG

Ad-hoc

Viromed Medical AG: Aufsichtsratsvorsitzender legt Mandat aus Altersgründen mit sofortiger Wirkung nieder – Gerichtliche Bestellung von Dr. Jan Delphendahl als Nachfolger beabsichtigt

9 April 2024

07:30 Corporate DE